Business Context and Reporting Period
Company: Orthofix Medical Inc. (OFIX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 5, 2026
Reporting Period: First Quarter ended March 31, 2026
Context: The filing announces the Company's financial results for the first quarter of 2026 via a press release (Exhibit 99.1) and includes a corporate investor relations presentation (Exhibit 99.2).
Key Financial Metrics
The provided text serves as a cover document and disclosure of non-GAAP methodologies. It does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the period ended March 31, 2026. These figures are referenced as being contained in the attached press release (Exhibit 99.1) and the Form 10-Q, which are not included in the input text.
Non-GAAP Measures Defined: The Company utilizes the following metrics to evaluate performance:
- Constant Currency: Net sales adjusted for foreign currency rate fluctuations.
- Free Cash Flow: Operating cash flow less capital expenditures.
- Adjusted Gross Profit/Margin: GAAP gross profit excluding specific cost of goods sold items.
- Adjusted Net Income (Loss): GAAP net loss excluding specific non-operating and one-time items.
- Adjusted EBITDA: Primary metric for the chief operating decision maker, excluding interest, taxes, depreciation, amortization, and specific adjustments.
Material Changes and Non-GAAP Adjustments
While specific comparative financial changes are not quantified in this text, the filing details the specific items excluded from non-GAAP measures to reflect core operating performance. These adjustments include:
- Share-based compensation: Non-cash expenses related to stock options, RSUs, and cash-settled awards.
- Foreign exchange impact: Gains and losses on currency transactions.
- SeaSpine merger-related costs: Integration, severance, retention, product rationalization, and professional fees from the January 2023 merger.
- Strategic investments: Due diligence and integration costs unrelated to the SeaSpine merger.
- Acquisition-related fair value adjustments: Contingent consideration remeasurement, in-process R&D (IPR&D) expensing, and inventory fair value amortization.
- Amortization/depreciation of acquired assets: Intangible assets and goodwill impairments from business combinations.
- Interest and investment gains/losses: Non-cash gains or losses on investments.
- Litigation and investigation costs: Legal settlements and costs related to the Board investigation resulting in the departure of three former executive officers.
- M6 product line restructuring: Severance and impairment charges from discontinuing M6 artificial disc product lines.
- Employee retention credit: Refunds and fees related to the CARES Act payroll tax credit.
- Tax rate adjustment: Normalized to a long-term effective tax rate of 28% for 2025 and 2026.
Guidance, Outlook, and Risks
Outlook and Tax Assumptions: Management expects a long-term normalized effective tax rate of 28% for 2025 and 2026. Actual GAAP tax expense may differ due to tax audits, deferred tax asset realization, and reconciling items.
Regulation FD Disclosure: The Company intends to use the investor relations presentation (Exhibit 99.2) for presentations to investors and analysts during the fiscal year ending December 31, 2026.
Risks and Limitations: The filing notes that non-GAAP measures have limitations, including the exclusion of economic costs that affect cash flows. Investors are encouraged to review reconciliations to GAAP measures for a complete picture.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net income, and cash flow figures, as they are not present in this text.
- Verify the reconciliation tables between GAAP and Adjusted EBITDA/Net Income to understand the magnitude of the excluded items (e.g., SeaSpine merger costs, M6 restructuring).
- Confirm the impact of the 28% normalized tax rate assumption versus the actual GAAP effective tax rate reported in the Form 10-Q.
- Assess the status of litigation and investigation costs related to the departure of former executive officers.
- Examine the Form 10-Q for the quarter ended March 31, 2026, for detailed breakdowns of share-based compensation and foreign exchange impacts.